HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>Last week, the 7th national volume-based purchase (VBP) began, involving 208 product specifications and 59 varieties.</li>
<li>We summaries the competitive landscape and outlook of both domestic and foreign pharmaceutical companies in this VBP.</li>
<li>Most investors may not have experienced July 22, 2015, so there is no reason to dismiss the prospects of China's healthcare industry because of the correction in the short term. </li>
</ul>


Last week, the 7th national volume-based purchase (VBP) began, involving 208 product specifications and 59 varieties.
We summaries the competitive landscape and outlook of both domestic and foreign pharmaceutical companies in this VBP.
Most investors may not have experienced July 22, 2015, so there is no reason to dismiss the prospects of China's healthcare industry because of the correction in the short term. 


China Healthcare Weekly (Jan.28) - 7th National VBP, Taking History as a Mirror, Confidence Rebuilt

<ul>
<li>The executive meeting of the State Council last week formally mentioned to include dental implants in the centralized procurement.</li>
<li>We analyzed what the potential impact and trends could be after the centralized procurement is applied to dental implants. </li>
<li>We listed the 16 major varieties that are likely to be included in the 7th national VBP this year. </li>
</ul>


The executive meeting of the State Council last week formally mentioned to include dental implants in the centralized procurement.
We analyzed what the potential impact and trends could be after the centralized procurement is applied to dental implants. 
We listed the 16 major varieties that are likely to be included in the 7th national VBP this year. 


China Healthcare Weekly (Jan.14) - Impact on Dental Implant VBP, Prediction on 7th National VBP 2022

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of July 17th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Knowledge Atlas, Alibaba, Ntes, Iluvatar Corex, Gigadevice, Kingboard Laminates, Tencent, Sinopec, Hua Hong Semi.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of July 17th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Knowledge Atlas, Alibaba, Ntes, Iluvatar Corex, Gigadevice, Kingboard Laminates, Tencent, Sinopec, Hua Hong Semi.


HK Connect Flows Weekly (Jul 17th): Knowledge Atlas, Alibaba, Ntes, Iluvatar Corex, Gigadevice

<ul>
<li>Last Friday, the 6th national volume-based purchase (VBP) for insulin released results.</li>
<li>The NHSA issued relevant documents and proposed to implement unified access management for medical consumables, which means that more medical consumables would be included in centralized procurement.</li>
<li>The NHC issued a document promoting the standardized development of digital healthcare industry, which would bring varying degrees of influence to medical institutions and enterprises providing online healthcare services.</li>
</ul>


Last Friday, the 6th national volume-based purchase (VBP) for insulin released results.
The NHSA issued relevant documents and proposed to implement unified access management for medical consumables, which means that more medical consumables would be included in centralized procurement.
The NHC issued a document promoting the standardized development of digital healthcare industry, which would bring varying degrees of influence to medical institutions and enterprises providing online healthcare services.


China Healthcare Weekly (Nov.26)-Insulin VBP Results, Key Policy On Consumables & Digital Healthcare

Industry viewpoints:<ul>
<li>The recent centralized procurement on spring coil in Hebei province could be a warning to the relevant enterprises.</li>
<li>The NHSA pointed out that it will explore feasible ways to include dental items into the payment scope of commercial insurance.</li>
<li>We expect to see AI deeply integrated into the new drug development process and revolutionize the industry in the future.</li>
</ul>Company news:News about the updated progress on new drugs and cooperation agreement of <a href="https://www.smartkarma.com/entities/akeso-biopharma-inc" target="_blank" data-smartkarma-citation="entities:28830:1" rel="noopener">Akeso Biopharma Inc (9926 HK)</a>, <a href="https://www.smartkarma.com/entities/cspc-pharmaceutical-group-ltd" target="_blank" data-smartkarma-citation="entities:229:1" rel="noopener">CSPC Pharmaceutical Group (1093 HK)</a> and <a href="https://www.smartkarma.com/entities/everest-medicines-ltd" target="_blank" data-smartkarma-citation="entities:29224:1" rel="noopener">Everest Medicines (1952 HK)</a>. Market review:Last week, stock price for healthcare sector in A share increased 3.74%, while CSI 300 decreased 0.37% over the same period of time.Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Industry viewpoints:
The recent centralized procurement on spring coil in Hebei province could be a warning to the relevant enterprises.
The NHSA pointed out that it will explore feasible ways to include dental items into the payment scope of commercial insurance.
We expect to see AI deeply integrated into the new drug development process and revolutionize the industry in the future.
Company news:News about the updated progress on new drugs and cooperation agreement of Akeso Biopharma Inc (9926 HK), CSPC Pharmaceutical Group (1093 HK) and Everest Medicines (1952 HK). Market review:Last week, stock price for healthcare sector in A share increased 3.74%, while CSI 300 decreased 0.37% over the same period of time.Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China Healthcare Weekly (Sep.24) - VBP on Neuro-Intervention, Payment System Changes, AI in Drug R&D

China

CSPC Pharmaceutical Group Limited is a prominent Chinese pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products, including innovative drugs and bulk drugs. Its key products include innovative drugs for nervous system diseases, oncology, anti-infectives, and cardiovascular diseases, as well as bulk products like vitamin C, antibiotics, and caffeine. The company was formally established in 1997 and is headquartered in Shijiazhuang, Hebei Province, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CSPC Pharmaceutical (1093 HK)

China Healthcare Weekly (Jan.28) - 7th National VBP, Taking History as a Mirror, Confidence Rebuilt

We analyzed the competitive landscape of 7th national VBP. Taking history as a mirror, the 2015 healthcare reform could be a good reference.So,...

Xinyao (Criss) Wang

China Healthcare Weekly (Jan.14) - Impact on Dental Implant VBP, Prediction on 7th National VBP 2022

This insight analyzed the centralized procurement on dental implants and its impact and trends, as well as the prediction of 16 major varieties...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Jul 17th): Knowledge Atlas, Alibaba, Ntes, Iluvatar Corex, Gigadevice

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Knowledge Atlas (2513 HK), Alibaba (9988 HK), Ntes (9999...

Ke Yan, CFA, FRM

China Healthcare Weekly (Nov.26)-Insulin VBP Results, Key Policy On Consumables & Digital Healthcare

This article analyzed the 6th VBP results on insulin, the new and key policies about unified access management on medical consumables and the...

Xinyao (Criss) Wang

China Healthcare Weekly (Sep.24) - VBP on Neuro-Intervention, Payment System Changes, AI in Drug R&D

This article analyzed the centralized procurement on spring coil in Hebei province, commercial insurance coverage for dental items, AI in new drug...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)